IMV’s current clinical strategy focuses on combination immuno-oncology therapies incorporating our lead therapeutic cancer vaccine, DPX-Survivac, for advanced ovarian cancer and diffuse large B-cell lymphoma (DLBCL). Both of these tumor types are associated with poor outcomes and are thus high unmet medical needs.
We are currently engaged in two triple-combination immunotherapy trials leveraging DPX-Survivac and metronomic cyclophosphamide with leading immuno-modulators in advanced ovarian cancer:
Our goal with these programs is to confirm preliminary observations that DPX-Survivac may increase the vulnerability of these hard-to-treat tumors, while improving the utility of anti-cancer activity of these advanced agents.
Early clinical investigation of a second agent, DPX-E7, in human papillomavirus (HPV) cervical cancer is being pursued in an academic collaboration led by the Dana-Farber Cancer Institute.
Recurrent Ovarian Cancer
Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer
Recurrent Survivin-Expressing DLBCL
Phase 2 Study of DPX-Survivac Vaccine, Pembrolizumab and Cyclophosphamide in Patients With Recurrent Survivin-Expressing DLBCL
Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Working at IMV brings you to the forefront of cutting-edge science and research for cancer and other serious diseases. We’ve worked hard to build a culture of innovation and collaboration.Learn more about life at IMV